Stock Under $10 with 50-100% upside potential - 14 Days FREE!

Hospice Provider Releases Quality Data, Setting Benchmarks For Industry

SCOTTSDALE, Ariz., Dec. 1, 2012 /PRNewswire/ --  Hospice Compassus, a Nashville, Tenn.-based company that operates a nationwide network of hospice programs, has become the first hospice provider in the U.S. to publicly reveal patient quality data. The announcement was made today during a national hospice and palliative care physicians conference held by the company. The data shows significant achievements toward establishing and continuing to raise industry benchmarks after a year of reporting quality data at more than 50 community-based programs nationwide.

In 2011, Hospice Compassus vowed to lead the industry by proactively measuring and reporting on its performance and identified three specific quality metrics as the measure of success:

  • Percent of patients in pain at admission that have their pain controlled to their satisfaction within 48 hours;
  • Percent of families reporting that they received the ideal amount of education and preparation regarding their loved one's disease progression, treatments and medications, and;
  • Percent of patients that had pain above their self-identified threshold anytime during the last week of life.

Since voluntary reporting began in 2011 through October of this year, Hospice Compassus programs have achieved marked improvement in all these quality metrics:

  • The percentage of patients who had pain controlled in the first 48 hours improved from 76 percent to 81 percent for the entire company with one-third of Hospice Compassus programs improving to 97 percent.
  • The percentage of families reporting they received adequate education regarding medication, treatment and symptoms continued to remain high, improving from 84 percent to 85 percent.
  • The percentage of patients reporting pain above their self-identified threshold during the last week of life decreased from 23 percent to 16 percent.

Hospice Compassus selected quality metrics for its own national quality initiative in 2011 prior to establishment of Centers for Medicare and Medicaid Services requirements in 2012. The company's collection, measurement, and reporting of data is part of an ongoing effort to set and maintain credible, legitimate quality standards for the rest of the industry, and to continue improving on those standards until 100 percent compliance is achieved.

"With the significant milestones shared today, Hospice Compassus has established a solid benchmark and demonstrated how it's national initiative drives quality improvements," said Sean Morrison, MD, Hermann Merkin Professor of Palliative Care at the Mount Sinai School of Medicine and Director of the National Palliative Care Research Center, and past president of American Academy of Hospice and Palliative Care. "As we review our progress, address what has worked, what needs renewed focus, and chart our course for continued improvement over the next year and beyond, we are encouraged by the achievements to date and by the significant impact our ongoing efforts will have on hospice care in the U.S. and the patients and families we serve."

CMS has validated the company's approach by selecting one of the same measures as a requirement for all U.S. hospice providers to report beginning in 2013: Addressing pain within 48 hours of admission.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
TRY IT FREE

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Dividend Stock Advisor
TRY IT FREE
New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Real Money
TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:
  • Jim Cramer + 20 Wall Street pros
  • Intraday commentary & news
  • Real-time trading forum
  • Actionable trade ideas
Real Money Pro
TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass + 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 15,239.41 -55.09 -0.36%
NASDAQ 3,442.92 -16.50 -0.48%
S&P 500 1,642.85 -7.66 -0.46%
US 10 Yr 2.005% -0.018

Brokerage Partners

Advertising Partners
Special Features

Free Newsletters from TheStreet

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy. Manage Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs